compound introduction
(Rac)-Etavopivat ((Rac)-FT-4202) is an isomer of Etavopivat . Etavopivat is an orally active erythrocyte pyruvate kinase-R ( PKR ) activator that can be used in studies of sickle cell disease and other haemoglobinopathies. In Vitro Etavopivat (20 μM, 4 h) improves haemoglobin-oxygen affinity and reduces the sickle point (PoS) in human red blood cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Etavopivat (oral gavage, 3-22 mg/kg, once daily, 5 days) causes an increase in 2,3-DPG and ATP in crab-eating monkeys at doses of 8 mg/kg and 22 mg/kg . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid
